Robert Coury - Mylan

Robert Coury - Mylan
Total Compensation: $21.3 million

Details: Coury took a bit of a pay cut in his final year as Mylan's ($MYL) chief after steady raises from 2008 to 2010. His base salary jumped by about $800,000 to $1.78 million, and he saw increases in stock awards and incentive compensation, but his deferred compensation dropped by more than $3 million.

Coury will stay on as executive chairman of the genericsmaker, which plans to broaden its sales by launching its own prescription drugs in India, and Mylan is optimistic that the $17.5 million it paid for Pfizer's dry powder inhaler technology will help the company carve out a space in the world respiratory market.

Robert Coury - Mylan
Read more on

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.